Try our beta test site

Super-Selective Intraarterial Cerebral Infusion Of Temozolomide (Temodar) For Treatment Of Newly Diagnosed GBM And AA

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Feinstein Institute for Medical Research
Hofstra North Shore
Information provided by (Responsible Party):
John A. Boockvar, Feinstein Institute for Medical Research
ClinicalTrials.gov Identifier:
NCT01180816
First received: August 10, 2010
Last updated: January 30, 2017
Last verified: January 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2017
  Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)